Kiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target Raised to $35.00

Kiniksa Pharmaceuticals (NASDAQ:KNSA) had its target price raised by Evercore ISI from $30.00 to $35.00 in a research report report published on Wednesday, Benzinga reports. Evercore ISI currently has an outperform rating on the stock.

A number of other analysts have also recently weighed in on KNSA. Jefferies Financial Group began coverage on shares of Kiniksa Pharmaceuticals in a report on Friday, September 13th. They set a “buy” rating and a $40.00 price objective on the stock. Wedbush raised their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a report on Tuesday, July 23rd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $34.60.

Kiniksa Pharmaceuticals Trading Down 0.5 %

NASDAQ:KNSA traded down $0.11 during mid-day trading on Wednesday, hitting $22.48. The stock had a trading volume of 358,298 shares, compared to its average volume of 412,544. The stock has a 50-day simple moving average of $25.40 and a two-hundred day simple moving average of $22.46. The company has a market capitalization of $1.60 billion, a PE ratio of -160.52 and a beta of 0.33. Kiniksa Pharmaceuticals has a twelve month low of $14.12 and a twelve month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The firm had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm’s revenue was up 67.4% compared to the same quarter last year. During the same period last year, the business earned ($0.20) EPS. Sell-side analysts predict that Kiniksa Pharmaceuticals will post -0.38 EPS for the current fiscal year.

Insider Activity

In related news, COO Eben Tessari sold 17,500 shares of Kiniksa Pharmaceuticals stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $24.99, for a total value of $437,325.00. Following the transaction, the chief operating officer now directly owns 116,975 shares in the company, valued at $2,923,205.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider John F. Paolini sold 60,692 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total value of $1,585,275.04. Following the sale, the insider now directly owns 52,038 shares in the company, valued at $1,359,232.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Eben Tessari sold 17,500 shares of the business’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $24.99, for a total transaction of $437,325.00. Following the completion of the sale, the chief operating officer now owns 116,975 shares in the company, valued at $2,923,205.25. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 112,692 shares of company stock valued at $2,950,315 in the last ninety days. 54.57% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. CWM LLC increased its stake in shares of Kiniksa Pharmaceuticals by 443.0% during the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $61,000 after acquiring an additional 1,998 shares during the last quarter. nVerses Capital LLC acquired a new position in shares of Kiniksa Pharmaceuticals during the 3rd quarter valued at about $80,000. Lazard Asset Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals during the 1st quarter valued at about $71,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Kiniksa Pharmaceuticals during the 2nd quarter valued at about $100,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Kiniksa Pharmaceuticals by 65.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company’s stock valued at $195,000 after acquiring an additional 3,076 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.